TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31690647

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy (iCBT) consisting of seven weekly modules with support from a web therapist.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (CAU) with no constraints regarding the range of treatments.
Number of subjects: 0
Study: 28844200

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (6 liters per minute for 6 to 12 hours, delivered through an open face mask)
Number of subjects: 6629

Group type: COMPARATOR
Intervention: Ambient air
Number of subjects: 6629

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Number of subjects: 6629
Study: 24220935

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg/day (oral) in repeated cycles of 4-week on/2-week off schedule
Number of subjects: 750

Group type: COMPARATOR
Intervention: Interferon-α (IFN-α) 9 million units subcutaneously thrice weekly
Number of subjects: 750
Study: 22523198

Group type: EXPERIMENTAL
Intervention: zoledronic acid
Number of subjects: 643

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 643
Study: 19066303

Group type: EXPERIMENTAL
Intervention: GH bolus administered postabsorptively
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GH bolus administered in the fasting state (37.5 h)
Number of subjects: 10
Study: 17469890

Group type: EXPERIMENTAL
Intervention: 8-week hypnotic taper program with self-help CBT
Number of subjects: 53

Group type: COMPARATOR
Intervention: 8-week hypnotic taper program alone
Number of subjects: 53
Study: 16045027

Group type: EXPERIMENTAL
Intervention: Two-stage administration sedation method (with propofol plus midazolam)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine continuum administration sedation method
Number of subjects: 64
Study: 12216337

Group type: EXPERIMENTAL
Intervention: Yasmin (COC with drospirenone and ethinylestradiol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other COCs
Number of subjects: 0
Study: 9457025

Group type: EXPERIMENTAL
Intervention: Twin Block appliances
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 8585734

Group type: EXPERIMENTAL
Intervention: 400 mg of ofloxacin i.v. q12h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 400 mg of ciprofloxacin i.v. q12h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 400 mg of ofloxacin i.v. q12h plus 1 g of ceftazidime i.v. q8h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 400 mg of ciprofloxacin i.v. q12h plus 1 g of ceftazidime i.v. q8h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 400 mg of ofloxacin i.v. q12h plus 4 g of piperacillin i.v. q8h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 400 mg of ciprofloxacin i.v. q12h plus 4 g of piperacillin i.v. q8h
Number of subjects: 12
Study: 2376426

Group type: EXPERIMENTAL
Intervention: Preparation A (200 mg ibuprofen)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Preparation B (200 mg ibuprofen)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 10
Study: 6158257

Group type: EXPERIMENTAL
Intervention: Amipaque (metrizamide 370 mg I/ml)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Isopaque Coronar (metrizoate 370 mg I/ml)
Number of subjects: 52
Study: 30905265

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT) as part of the IAPT initiative
Number of subjects: 0
Study: 28599676

Group type: EXPERIMENTAL
Intervention: SPN + EN
Number of subjects: 125

Group type: COMPARATOR
Intervention: EN alone
Number of subjects: 125
Study: 25923462

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPre)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Coronary heart disease (CHD) group
Number of subjects: 40
Study: 23590407

Group type: EXPERIMENTAL
Intervention: Experimental pain model (hypertonic saline injection in infrapatellar fat pad)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (isotonic saline injection in contralateral infrapatellar fat pad)
Number of subjects: 17
Study: 21256045

Group type: EXPERIMENTAL
Intervention: Transfemoral (TF) approach
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Trans-apical (TA) approach
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional aortic valve surgery (AVR) control group
Number of subjects: 35
Study: 19583763

Group type: EXPERIMENTAL
Intervention: Panavia F 2.0
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PermaFlo DC
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Variolink II
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: RelyX Unicem
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Clearfil Core
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Self-adhesive resin cement
Number of subjects: 50
Study: 17357053

Group type: EXPERIMENTAL
Intervention: 3-drug EFV regimen (zidovudine/lamivudine plus EFV)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Triple-nucleoside regimen (zidovudine/lamivudine/abacavir)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 4-drug EFV regimen (zidovudine/lamivudine/abacavir plus EFV)
Number of subjects: 64
Study: 16859064

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (1 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyridoxine (5-100 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12624295

Group type: EXPERIMENTAL
Intervention: Impaired cardiac baroreceptor sensitivity (BRS) defined as BRS ≤ 5.0 ms/mm Hg
Number of subjects: 124

Group type: COMPARATOR
Intervention: Normal cardiac baroreceptor sensitivity (BRS) defined as BRS > 5.0 ms/mm Hg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cardiac BRS assessment using power spectral analysis techniques
Number of subjects: 124
Study: 10849042

Group type: EXPERIMENTAL
Intervention: Zolmitriptan, 5 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Rizatriptan, 10 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both zolmitriptan and rizatriptan
Number of subjects: 56
Study: 8656666

Group type: EXPERIMENTAL
Intervention: cilazapril, 5 mg once daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: atenolol, 100 mg once daily
Number of subjects: 40
Study: 1877363

Group type: EXPERIMENTAL
Intervention: Small meal
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Large meal
Number of subjects: 4

Group type: COMPARATOR
Intervention: Both small and large meals
Number of subjects: 4
Study: 6285721

Group type: EXPERIMENTAL
Intervention: Topical 5 percent acyclovir in polyethylene glycol
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 31487444

Group type: EXPERIMENTAL
Intervention: Nursing intervention based on motivational interview (3 sessions of 40 min each over 6 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional management of education (control group)
Number of subjects: 56
Study: 27849389

Group type: EXPERIMENTAL
Intervention: Core stability exercise
Number of subjects: 414

Group type: COMPARATOR
Intervention: General exercise
Number of subjects: 414
Study: 25117302

Group type: EXPERIMENTAL
Intervention: Serum GDF-15 levels in HD patients
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Serum GDF-15 levels
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: GDF-15 as an independent variable
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: CIMT assessment
Number of subjects: 87
Study: 23696515

Group type: EXPERIMENTAL
Intervention: MRI-PDFF
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MRS-PDFF
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MRI-PDFF and MRS-PDFF
Number of subjects: 50
Study: 20925971

Group type: EXPERIMENTAL
Intervention: Risperidone or Olanzapine
Number of subjects: 628
Study: 19323930

Group type: EXPERIMENTAL
Intervention: Intensive statin (80 mg simvastatin for 7 days)
Number of subjects: 228
Study: 17320304

Group type: EXPERIMENTAL
Intervention: School-wide no smoking strategy and six-session smoking prevention curriculum
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: School-wide no smoking strategy
Number of subjects: 469

Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 469
Study: 14744507

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11158043

Group type: EXPERIMENTAL
Intervention: Aldosterone (0.5 mg) after esmolol pretreatment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Aldosterone (0.5 mg) after dobutamine pretreatment
Number of subjects: 18
Study: 9576193

Group type: EXPERIMENTAL
Intervention: Intensive induction and consolidation chemotherapy (4 courses)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Autologous bone marrow transplant (A-BMT)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Allogeneic bone marrow transplant (allo-BMT)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy
Number of subjects: 359

Group type: COMPARATOR
Intervention: Thioguanine
Number of subjects: 359

Group type: COMPARATOR
Intervention: Etoposide
Number of subjects: 359
Study: 7889896

Group type: EXPERIMENTAL
Intervention: Long-stay (LS) group, retained in hospital for full nutritional rehabilitation (mean 40 days)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Short-stay (SS) group, discharged immediately (mean 18 days) for standard Health Service care at home for 6 months plus high-energy supplement (3.31 MJ with 20.6 g protein daily) for first 3 months
Number of subjects: 81
Study: 3225427

Group type: EXPERIMENTAL
Intervention: Intravenous cefamandole and oral cephalexin
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (intravenous and oral)
Number of subjects: 87
Study: 31793099

Group type: EXPERIMENTAL
Intervention: Distraction methods (3D videos with VR goggles and optical illusion pictures)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study: 30579131

Group type: COMPARATOR
Intervention: Mindfully attending externally to the feared object (Ext)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Attending to both the object and their internal distress (Int/Ext)
Number of subjects: 48
Study: 28383710

Group type: EXPERIMENTAL
Intervention: ASP8477 (20/30 mg BID)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: ASP8477
Number of subjects: 132
Study: 25257259

Group type: EXPERIMENTAL
Intervention: L-Tyrosine (TYR) supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study: 24171985

Group type: EXPERIMENTAL
Intervention: GTR membrane + bone graft (test)
Number of subjects: 20

Group type: COMPARATOR
Intervention: OFD (control)
Number of subjects: 20
Study: 22355992

Group type: EXPERIMENTAL
Intervention: High Voltage Pulsed Galvanic Stimulation (HVPGS)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Proprioceptive Neuromuscular Facilitation (PNF) technique
Number of subjects: 33
Study: 19162114

Group type: EXPERIMENTAL
Intervention: RIX4414 co-administered with OPV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo co-administered with OPV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RIX4414 without OPV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo without OPV
Number of subjects: 0
Study: 17290044

Group type: EXPERIMENTAL
Intervention: Induced sputum measurement
Number of subjects: 57
Study: 15566914

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty
Number of subjects: 102

Group type: COMPARATOR
Intervention: Off-pump left internal mammary artery bypass grafting
Number of subjects: 102
Study: 12362748

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10446946

Group type: EXPERIMENTAL
Intervention: Hyperglycemia (blood glucose 9 to 11 mmol/L)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Losartan administration during hyperglycemia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: AngII infusion (1.5 ng/kg per min) during hyperglycemia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: AngII infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Euglycemia (blood glucose 4 to 6 mmol/L)
Number of subjects: 10
Study: 8683087

Group type: EXPERIMENTAL
Intervention: ICPs with < 4 years of surveillance experience
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ICPs with >= 4 years of surveillance experience
Number of subjects: 16

Group type: COMPARATOR
Intervention: All ICP-years observed
Number of subjects: 16
Study: 2223359

Group type: EXPERIMENTAL
Intervention: 1% end‐tidal isoflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.5% halothane
Number of subjects: 20
Study: 667192

Group type: EXPERIMENTAL
Intervention: Biofeedback group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 30676648

Group type: EXPERIMENTAL
Intervention: Individuation instructions for recognizing other-age faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Categorization task performance
Number of subjects: 0
Study: 28863912

Group type: EXPERIMENTAL
Intervention: 2-premolar extraction protocol in Class II malocclusion patients
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 4-premolar extractions in Class II malocclusion patients
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 4-premolar extractions in Class I malocclusion patients
Number of subjects: 105
Study: 25864723

Group type: EXPERIMENTAL
Intervention: Non-intubated state (conscious sedation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intubated state (general anesthesia)
Number of subjects: 0
Study: 23721753

Group type: EXPERIMENTAL
Intervention: Blunt abdominal entry
Number of subjects: 15935

Group type: COMPARATOR
Intervention: Sharp abdominal entry
Number of subjects: 15935

Group type: EXPERIMENTAL
Intervention: Exteriorisation of the uterus for repair
Number of subjects: 15935

Group type: COMPARATOR
Intervention: Intra-abdominal repair
Number of subjects: 15935

Group type: EXPERIMENTAL
Intervention: Single-layer closure of the uterus
Number of subjects: 15935

Group type: COMPARATOR
Intervention: Double-layer closure of the uterus
Number of subjects: 15935

Group type: EXPERIMENTAL
Intervention: Closure of the peritoneum
Number of subjects: 15935

Group type: COMPARATOR
Intervention: Non-closure of the peritoneum
Number of subjects: 15935

Group type: EXPERIMENTAL
Intervention: Chromic catgut for uterine repair
Number of subjects: 15935

Group type: COMPARATOR
Intervention: Polyglactin-910 for uterine repair
Number of subjects: 15935
Study: 21843028

Group type: EXPERIMENTAL
Intervention: Quixfil (QF)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Filtek Supreme (FS)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Filtek Silorane (SI)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: LED Bluephase C8 (LED)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Halogen Translux Energy (HTE)
Number of subjects: 36
Study: 19661833

Group type: EXPERIMENTAL
Intervention: EPP followed by radical hemithorax radiotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Continued best care
Number of subjects: 50
Study: 17944641

Group type: EXPERIMENTAL
Intervention: Laryngeal Tube Suction (LTS II)
Number of subjects: 100

Group type: COMPARATOR
Intervention: LMA-ProSeal
Number of subjects: 100
Study: 15569162

Group type: EXPERIMENTAL
Intervention: Thawed cryoprecipitate stored for 6 h at room temperature
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Type ORh+ blood
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Units stored <6 months
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Bacteriological culture studies
Number of subjects: 37
Study: 11739302

Group type: EXPERIMENTAL
Intervention: Triglycerides >200 mg/dL
Number of subjects: 11177

Group type: EXPERIMENTAL
Intervention: 5% decrease in %HDL
Number of subjects: 11177

Group type: EXPERIMENTAL
Intervention: High triglycerides
Number of subjects: 11177

Group type: EXPERIMENTAL
Intervention: High %HDL
Number of subjects: 11177
Study: 9166835

Group type: EXPERIMENTAL
Intervention: VNCOP-B plus G-CSF
Number of subjects: 149

Group type: COMPARATOR
Intervention: VNCOP-B alone (Control)
Number of subjects: 149
Study: 1586330

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (3mg) gel
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sterile K‐Y Jelly
Number of subjects: 59
Study: 3896614

Group type: EXPERIMENTAL
Intervention: Single-view mammography screening (ASP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31484579

Group type: EXPERIMENTAL
Intervention: SHARECONTRACEPT decision-making tool
Number of subjects: 1708

Group type: COMPARATOR
Intervention: Conventional contraceptive counselling
Number of subjects: 1708
Study: 28159826

Group type: EXPERIMENTAL
Intervention: Aggressive titration of vasoactive HF therapies
Number of subjects: 38
Study: 25487877

Group type: EXPERIMENTAL
Intervention: Ripasudil 0.2%
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ripasudil 0.4%
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 23323969

Group type: EXPERIMENTAL
Intervention: Super taster (ST) or Sweet liker (SL)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Sweet liker (SL) + Super taster (ST)
Number of subjects: 196
Study: 21107513

Group type: EXPERIMENTAL
Intervention: Kettlebell training (ballistic full‐body kettlebell exercise 3 times per week for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 19728940

Group type: EXPERIMENTAL
Intervention: Hasson cannula
Number of subjects: 120

Group type: COMPARATOR
Intervention: Veress needle
Number of subjects: 120
Study: 17214949

Group type: EXPERIMENTAL
Intervention: Workplace safety programs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Safety training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attention to safety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Safety classes and training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dedicated safety teams/individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indirect costs of workplace injury
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investment in workplace safety
Number of subjects: 0
Study: 14998098

Group type: EXPERIMENTAL
Intervention: Skilled soccer and field hockey players
Number of subjects: 0

Group type: COMPARATOR
Intervention: Skilled soccer, field hockey, and volleyball players
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skilled field hockey and soccer players
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less skilled participants
Number of subjects: 0
Study: 11378012

Group type: EXPERIMENTAL
Intervention: Carvedilol (beta-blocker)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous non-selective endothelin antagonist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cardioversion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etanercept (TNF receptor analogue)
Number of subjects: 0
Study: 9131947

Group type: EXPERIMENTAL
Intervention: Single dose inhalation of fluticasone propionate (1000 micrograms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Repeated inhalations of fluticasone propionate (1000 micrograms twice daily for 7 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous dose of fluticasone propionate (20 micrograms) as a reference
Number of subjects: 12
Study: 8111807

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 230

Group type: COMPARATOR
Intervention: Nifedipine-ER
Number of subjects: 230
Study: 3298405

Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) at 45 mg/kg/day by continuous infusion for 28 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) at 45 mg/kg/day by intermittent 8-hourly infusion for 28 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) treatment
Number of subjects: 20
Study: 2583756

Group type: EXPERIMENTAL
Intervention: Group B (120 mg elemental iron as ferrous sulphate daily)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Group C (240 mg elemental iron as ferrous sulphate daily)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Group A (60 mg elemental iron as ferrous sulphate daily)
Number of subjects: 110
Study: 31615182

Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional rehabilitation
Number of subjects: 80
Study: 28800039

Group type: EXPERIMENTAL
Intervention: Individually tailored intelligent physical exercise training (IPET) - 1 hour high-intensity once a week, plus 30 minutes moderate-intensity physical activity 6 days a week during leisure-time
Number of subjects: 387

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 387
Study: 25500684

Group type: EXPERIMENTAL
Intervention: Intravenous sodium valproate (20 mg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intramuscular haloperidol (5 mg/1 ml)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intramuscular haloperidol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intravenous sodium valproate
Number of subjects: 80
Study: 24001246

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) with monetary vouchers for stimulant-negative urine samples
Number of subjects: 82
Study: 21521543

Group type: EXPERIMENTAL
Intervention: DHA-containing functional food (DHA-FF)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 19234078

Group type: EXPERIMENTAL
Intervention: Self-reports of depression, moodiness, and prior appointment avoidance due to fear
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Reported anxiety or nervousness
Number of subjects: 357
Study: 16585858

Group type: EXPERIMENTAL
Intervention: Radiofrequency volumetric tissue reduction (RFVTR)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 12777542

Group type: EXPERIMENTAL
Intervention: Media education campaign
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Community mobilization strategy
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Control area
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Media campaign
Number of subjects: 1500
Study: 10867294

Group type: EXPERIMENTAL
Intervention: Motivational enhancement intervention session
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard anger management classes
Number of subjects: 41